CE Search Engine Logo

TROP2 Expression: An Evolving Targeted Approach for Patients with Advanced NSCLC

Access Activity

Overview / Abstract:

Target Audience
Thoracic and medical oncologists, pulmonologists, pathologists, NPs and Pas, oncology nurses and other HCPs involved in the care of patients with lung cancer.

Learning Objectives
At the conclusion of this activity, participants will be able to:

Describe TROP2 as a biomarker, prognostic indicator, and drug target for NSCLC
Evaluate the impact of overexpression and upregulation of TROP2 in NSCLC
Summarize the unique design principles of ADC anti-TROP2 therapies
Compare and contrast the mechanism of action for novel anti-TROP2 therapies
Review current clinical trials evaluating anti-TROP2 ADCs in solid tumor cancers, including NSCLC

Expiration

Sep 01, 2021

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.0

Accreditation

ACCME, ANCC, ACPE

Presenters / Authors / Faculty

Edward Garon, MD, MS
Aaron Lisberg, MD

Sponsors / Supporters / Grant Providers

Daiichi Sankyo

Keywords / Search Terms

Relias LLC Relias, Free CME, TROP2, Advanced NSCLC Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map